Navigation Links
RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
Date:12/1/2011

REDWOOD CITY, Calif., Dec. 1, 2011 /PRNewswire/ -- Clinical Investigators for Arstasis, Inc., reported the results of the RECITAL study during the recent TCT Meeting in San Francisco, demonstrating the Arstasis access device enables rapid, secure, implant-free closure of femoral arteries after cardiac catheterization procedures. The device creates a unique access pathway, called an Arstaotomy, into the femoral artery through which catheterization procedures are performed.

RECITAL is a prospective, multi-center clinical study that enrolled 351 patients to assess device and procedural success of key post-catheterization recovery measures that influence the safety and speed toward discharging those patients from the hospital. The results indicate that hospitals may be able to both reduce current complication rates and eliminate costs from longer hospitalizations in this patient population.

Key results of the RECITAL study showed that device deployment was successful in 97% of RECITAL patients and femoral bleeding stopped after only 3 minutes for diagnostic angiogram patients and 5 minutes for anti-coagulated patients undergoing a percutaneous coronary intervention (PCI). Most of the patients were able to sit up within 15-30 minutes and were able to walk in about one hour after an angiogram and two hours after a PCI. Investigators found no major complications related to use of the Arstasis device.

Dr. Dale Wortham, University of Tennessee  Medical Center, Knoxville and RECITAL Study Principal Investigator, commented, "Introducing foreign materials in a patient to close the femoral artery can be problematic. We were very pleased the RECITAL Study demonstrated the Arstaotomy procedure can deliver closure-like hemostasis and ambulation times without the use of a temporary or permanent implant."

The RECITAL Study illustrates the Arstaotomy procedure can potentially accelerate patient throughput, delivering a quicker, more comfortable experience for the patient while reducing hospital resource use and overall cost per patient.

Separately, Arstasis announced the appointment of David I. Bruce to the position of President and CEO. The company's founder, Bruce Modesitt, who has been CEO since its inception in 2004, will focus on expanding the product platform as Chief Technology Officer.

"At this point in our company's history, we're delighted to attract a seasoned CEO with repeat successes in managing early market penetration for novel medical devices," commented Bruce Modesitt, "and I look forward to David's leadership in accelerating our business growth."

New CEO David Bruce said, "I'm pleased to be joining the Arstasis team as we announce the results of our first U.S. clinical trial. RECITAL demonstrates the Arstaotomy procedure helps minimize complications, speed recovery and enable earlier discharge. With our investigators and initial customers showing outstanding results, we are positioned to achieve broader adoption into the ten million arterial catheterization procedures performed worldwide each year."

The AXERA™ Access Device is a breakthrough femoral artery access tool that quickly creates a long, ultra-low angle arteriotomy, the Arstaotomy, resulting in significant tissue-upon-tissue overlap in the artery wall. The Arstaotomy procedure requires minimal manual compression to provide secure arterial closure with no foreign body implants thereby eliminating the risk of infections and thromboembolic events related to vascular implants.

Arstasis, Inc. is headquartered in Redwood City, CA. Additional information about the RECITAL Study, Arstaotomy procedure and AXERA Access Device is available at www.arstasis.com.

CONTACT:
Mark Page
Sr. Director, Marketing
Arstasis, Inc.
650-508-1549


'/>"/>
SOURCE Arstasis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
2. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
4. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
5. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
6. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
7. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
8. Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
9. Perceptive Informatics® Global Survey Results Indicate Wide Use of Industry-Standard Medical Imaging Metrics to Meet Study Milestones
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
11. goBalto Sponsors Tufts CSDD Study to Benchmark the Clinical Trial Initiation Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today ... Inc.,s Supplier Horizon Award . One ... Guerbet was recognized for its support of Premier members ... through clinical excellence, and commitment to lower costs. ... receive this recognition of our outstanding customer service from ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. Stock-Callers.com assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
Breaking Medicine News(10 mins):